Mission Statement, Vision, & Core Values (2024) of Esperion Therapeutics, Inc. (ESPR)

An Overview of Esperion Therapeutics, Inc. (ESPR)

General Summary of Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics, Inc. was incorporated in Delaware in January 2008 and commenced operations in April 2008. The company focuses on developing and commercializing therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), both of which received FDA approval in February 2020. NEXLETOL became commercially available on March 30, 2020, while NEXLIZET followed on June 4, 2020. In May 2024, the European Commission approved expanded indications for both products to reduce cardiovascular risk in patients with or at high risk for atherosclerotic cardiovascular disease.

As of 2024, Esperion's sales figures have shown significant growth. For the nine months ended September 30, 2024, net product sales reached $84.2 million compared to $57.6 million for the same period in 2023, reflecting an increase of approximately $26.6 million. The growth is primarily attributed to prescription volume increases for NEXLETOL and NEXLIZET.

Company's Financial Performance in the Latest Financial Reports

In the latest financial reporting period, Esperion Therapeutics reported record-breaking revenue. For the three months ended September 30, 2024, total revenue was $51.6 million, which included:

• Product sales, net: $31.1 million
• Collaboration revenue: $20.5 million

This represented a substantial increase from the three months ended September 30, 2023, where total revenue was $34.0 million, comprised of:

• Product sales, net: $20.3 million
• Collaboration revenue: $13.7 million

For the nine months ended September 30, 2024, total revenue soared to $263.2 million, with key figures as follows:

• Product sales, net: $84.2 million
• Collaboration revenue: $179.0 million

In comparison, total revenue for the nine months ended September 30, 2023, was $84.1 million, with:

• Product sales, net: $57.6 million
• Collaboration revenue: $26.5 million

Esperion's operating expenses for the three months ended September 30, 2024, were $67.7 million, compared to $61.5 million for the same period in 2023. The breakdown of operating expenses is as follows:

Esperion reported a net loss of $29.5 million for the three months ended September 30, 2024, compared to a net loss of $41.3 million for the same period in 2023. For the nine months ended September 30, 2024, the net loss was $30.4 million, a significant improvement from a loss of $152.9 million in the previous year.

Introduction to Company as a Leader in the Industry

Esperion Therapeutics, Inc. is recognized as a leader in the cholesterol-lowering medication market, particularly with its innovative products NEXLETOL and NEXLIZET. The company's strategic focus on developing effective therapies to manage LDL-C levels positions it strongly within the cardiovascular therapeutic area. The expanded indications for both NEXLETOL and NEXLIZET, approved in 2024, underscore the company's commitment to addressing cardiovascular risks effectively.

With a solid foundation in research and development, along with growing sales figures, Esperion is poised for continued success in the pharmaceutical industry. The company’s innovative approach combined with its financial growth highlights its role as a prominent player in the sector.

Mission Statement of Esperion Therapeutics, Inc. (ESPR)

Overview of Esperion Therapeutics, Inc. Mission Statement

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is dedicated to addressing unmet medical needs in cardiovascular disease through innovative therapies. The company’s mission statement reflects its commitment to developing and commercializing high-quality, non-statin medications that significantly improve patient outcomes.

Core Component 1: Commitment to Patients

Esperion's mission emphasizes a strong commitment to patients, focusing on delivering medications that help manage elevated low-density lipoprotein cholesterol (LDL-C) levels. This is particularly crucial for individuals who either cannot tolerate statin therapy or for whom traditional treatments are insufficient. In 2024, Esperion reported product sales of $84.2 million, primarily driven by its flagship products, NEXLETOL and NEXLIZET, which are designed to lower LDL-C and reduce cardiovascular risks.

Core Component 2: Innovation in Therapeutics

Innovation is at the heart of Esperion’s mission. The company focuses on developing unique oral therapies, including bempedoic acid and the bempedoic acid/ezetimibe combination, which have been validated through rigorous clinical trials. For instance, the CLEAR Outcomes trial demonstrated a significant 21.1% reduction in LDL-C levels and a 13% lower risk of major cardiovascular events compared to placebo. In 2024, the company expanded indications for these products to include cardiovascular risk reduction.

Core Component 3: Collaborative Approach

Esperion adopts a collaborative approach in its mission, partnering with various stakeholders to enhance its research and development capabilities. As of September 30, 2024, collaboration revenue surged to $179 million, representing a substantial increase from $26.5 million in the prior year. This growth is attributed to strategic collaborations that enhance product accessibility and support ongoing clinical studies.

As Esperion continues to execute its mission, it remains focused on improving patient health outcomes through innovative treatments and collaborative partnerships, thereby positioning itself as a leader in the biopharmaceutical industry dedicated to cardiovascular health.

Vision Statement of Esperion Therapeutics, Inc. (ESPR)

Vision Statement of Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics aims to transform the treatment of cardiovascular diseases through innovative, non-statin therapies that address unmet medical needs. Their vision is centered on delivering effective, once-daily oral medications that lower LDL-C levels and reduce cardiovascular risks.

Innovative Therapeutics

Esperion focuses on developing first-in-class drugs such as NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe). These medications are designed to lower LDL-C and cardiovascular risk without the use of statins. The FDA approved NEXLETOL in February 2020, and it received an expanded indication for cardiovascular risk reduction in March 2024.

Commitment to Patient Care

Esperion’s vision emphasizes patient-centric care, targeting individuals who are at high risk for cardiovascular events and struggle with elevated LDL-C levels. The goal is to provide effective alternatives for those who are statin-intolerant or cannot achieve their LDL-C goals with existing therapies.

Global Reach and Collaboration

Esperion is committed to expanding its global footprint through strategic partnerships and collaborations. For instance, they have collaboration agreements with Otsuka Pharmaceutical Co., Ltd, which is set to file a New Drug Application in Japan by the end of 2024.

Focus on Research and Development

Research and development remain a core focus, with a commitment to advancing clinical trials and exploring new indications for existing products. For the nine months ended September 30, 2024, Esperion incurred $35.3 million in research and development expenses, a significant decrease from $68.4 million in the same period the previous year, primarily due to the completion of the CLEAR Outcomes study.

Financial Performance and Growth

Esperion's financial trajectory reflects its commitment to innovation and growth. For the nine months ended September 30, 2024, net product sales reached $84.2 million, compared to $57.6 million for the same period in 2023, marking an increase of $26.6 million. Additionally, collaboration revenue surged to $179.0 million from $26.5 million year-over-year, driven by enhanced product sales and partnerships.

Future Outlook

Esperion’s vision for the future includes ongoing innovation, expansion into new markets, and continued dedication to improving patient outcomes. The company anticipates further growth in product sales and collaboration revenue as they enhance their product offerings and expand their global reach.

Core Values of Esperion Therapeutics, Inc. (ESPR)

Integrity

Integrity is a fundamental core value at Esperion Therapeutics, reflecting the company's commitment to ethical practices, transparency, and accountability in all operations. This value is essential in building trust with stakeholders, including patients, healthcare providers, and investors.

Esperion demonstrates its commitment to integrity through rigorous compliance with regulatory standards and ethical guidelines in clinical trials. For instance, the company has adhered to the FDA's stringent requirements during the development and commercialization of its products, NEXLETOL and NEXLIZET, ensuring that all clinical data is accurately reported and ethically obtained.

Innovation

Innovation is at the heart of Esperion's mission to develop groundbreaking therapies for cardiovascular disease. The company invests heavily in research and development to create non-statin treatments that address unmet medical needs.

As of September 30, 2024, Esperion reported $35.3 million in research and development expenses, reflecting its dedication to advancing its innovative product pipeline. This includes the development of NEXLETOL, which received FDA approval in February 2020 and expanded indications in March 2024, showcasing the company's commitment to continuous improvement and innovation in lipid management therapies.

Collaboration

Collaboration is a vital core value for Esperion, as it fosters partnerships that enhance the company's capabilities and reach. The company collaborates with various organizations, including research institutions and pharmaceutical companies, to accelerate the development and commercialization of its products.

In May 2024, Esperion entered into a collaboration agreement with Daiichi Sankyo Co. Ltd, which allows for the development and commercialization of a bempedoic acid/ezetimibe/statin combination pill. This partnership is expected to significantly expand Esperion's market presence and enhance its product offerings.

Patient-Centricity

Patient-Centricity is a core value that guides Esperion's mission to prioritize the needs and well-being of patients. The company's products are designed specifically for patients who are unable to effectively manage their cholesterol levels with traditional statin therapies.

Esperion's commitment to patient-centricity is evident in the design of its clinical trials, which prioritize patient safety and efficacy of treatments. The CLEAR Outcomes study, which evaluated the cardiovascular benefits of NEXLETOL, involved over 3,000 patients, demonstrating the company's dedication to understanding and addressing patient needs.

Excellence

Excellence is a core value that reflects Esperion's pursuit of the highest standards in every aspect of its operations. The company strives for excellence in product development, clinical research, and customer service.

Esperion's excellence is highlighted by its successful FDA approval of NEXLETOL and NEXLIZET, which are both recognized as first-in-class therapies for lowering LDL-C. The company's performance metrics, including a net product revenue of $84.2 million for the nine months ended September 30, 2024, indicate its effective execution of business strategies aimed at achieving excellence.

Updated on 16 Nov 2024

Resources:

1. Esperion Therapeutics, Inc. (ESPR) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Esperion Therapeutics, Inc. (ESPR)' financial performance, including balance sheets, income statements, and cash flow statements.
2. SEC Filings – View Esperion Therapeutics, Inc. (ESPR)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.